logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Approves Abbott's FreeStyle InsuLinx Blood Glucose Monitoring System

Abbott Laboratories (ABT: Quote) announced that it has received U.S. Food and Drug Administration clearance for the FreeStyle InsuLinx Blood Glucose Monitoring System. The company said that the system included a touch-screen interface, automated logbook. The system also offers Personalization features, including the ability to upload weekly messages, pre-and post-meal markers and a personal photograph to the home screen.

This unique device is also equipped with built-in FreeStyle Auto-Assist software that enables patients to track progress, analyze trends and easily display data for their health care providers.

The FreeStyle InsuLinx System will be available to U.S. consumers within the coming months, the company said.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Burger chain Shake Shack Inc. said late Thursday that it has priced its initial public offering of 5 million Class A shares at $21 per share, which is above the previously estimated price range of $17 to $19 per share. The shares are expected to begin trading on the New York Stock Exchange on Friday, January 30 under the ticker symbol "SHAK." Google reported a higher fourth-quarter profit, driven by a 15 percent increase in revenues and one-time gains from the sale of Motorola Mobile business, somewhat offset by stock-based compensation expense and foreign exchange losses. Quarterly earnings and revenue missed Wall Street estimates, as ad revenues came under pressure. Online retailer Amazon.com, Inc. said Thursday after the markets closed that its fourth quarter fell 10.5% from last year, as higher expenses more than offset a 15% increase in sales. However, the company's quarterly earnings per share came in well above analysts' expectation, but its quarterly sales fell short of analysts' forecast.
comments powered by Disqus
RELATED NEWS
Trade ABT now with 
Follow RTT